ReviewAdvances in neurobiology2025
Impairment of Oligodendroglial Lineage Cells: An Important Player in the Pathogenesis of Psychiatric Disorders.
Review in Advances in neurobiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glial Cells in Behavioral and Psychological Symptoms of Alzheimer's Disease.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major psychiatric disorders like schizophrenia, depression and anxiety disorders, etc have serious impact on patients' health, but the pathogenesis remains unknown. With an extensive study on glial cells, their functions in psychiatric disorders have attracted much attention in recent years. Oligodendrocyte lineage cells (OLGs), as major myelination cells in the CNS, not only exhibit dynamic changes compatible with alterations in neurologic function but also regulate synaptic development and brain function from multiple aspects by interacting with neurons, astrocytes, and microglia. Concurrently, a growing number of studies have found extensive myelin loss and abnormal alterations of OLGs in the brains of patients with different types of psychiatric disorders. Moreover, impaired development and/or dysfunction of OLGs can lead to neuropsychiatric symptoms such as anxiety, depression, and social disorders by disrupting synaptic transmission or the glial network in animal models. Thus, targeting OLGs may represent a promising strategy for the treatment of psychiatric disorders.
Indexed as
Identifiers
40500506What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.